NA Proactive news snapshot: KULR Technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn. Revive Therapeutics, CleanSpark UPDATE ...

KULR Technology Group Inc (OTCQB:KULR) announced Thursday it had closed an $8 million offering backed by institutional investors. The offering included the sale of 6.4 million shares and warrants exercisable at $1.25 for a five-year period following the closing date. If the warrants are exercised in full for cash, KULR expects to receive around $8 million in additional gross proceeds, according to a release. KULR, a San Diego-based technology firm, develops, manufactures and licenses next-generation carbon fiber thermal management technologies for batteries and electronic systems. Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) announced Thursday it had closed a non-brokered private placement of convertible debentures to raise up to C$1,575,000. The biopharmaceutical company, which specializes in manufacturing hard pill cannabinoid formulations, said that the debentures are convertible at $0.80 per share and bear a two-year maturity date. Canntab has the right to prepay or redeem a portion or the entire principal amount plus any accrued interest with a minimum of 20 days notice prior to the redemption date, as well as the right to force conversion at the conversion price if the volume weighted average trading price exceeds C$1.20 for 15 straight days. Falcon Gold Corp (CVE:FG) (OTCPINK:FGLDF) closed an oversubscribed its non-brokered private placement on Thursday that raised C$800,000 in total subscriptions. The junior company will issue 6,666,665 units with each unit consisting of one common share at a deemed price of $0.12 and one non-transferable share purchase warrant at price of $0.20 per share. Each warrant has a term of 36 months following the acceptance date. The shares and warrants are subject to a 4 month hold. The use of proceeds will be for continued exploration on existing properties, outstanding payables, and general working capital.  CytoDyn Inc. (OTCQB:CYDY) has announced that the US Food and Drug Administration (FDA) has accepted the protocol the group submitted on December 28, 2020, for adding an open-label extension to its Phase 3 trial (CD12).  The late-stage biotechnology company, which is developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, noted that hospitals previously participating in the CD12 trial now have the option of enrolling additional eligible patients, with all patients receiving leronlimab. Treatment for eligible patients will continue until further notified by the FDA and/or CytoDyn. In a separate statement on Thursday, CytoDyn also announced that a research manuscript submitted by Dr Nicholas J. Agresti has been accepted for publication in the Journal of Translational Autoimmunity. Dr Agresti’s research findings were based on four critically ill COVID-19 patients treated with leronlimab under eIND. Revive Therapeutics Ltd. (CSE: RVV) (OTCMKTS:RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, has announced the appointment of Dr John Fahy as a Scientific and Clinical advisor to the company. He will assist in the expansion and the analysis of the clinical data on the ongoing US Food & Drug Administration (FDA) Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate coronavirus (COVID-19). Dr Fahy is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California San Francisco and is a director of UCSF’s severe asthma clinic. CleanSpark, Inc (NASDAQ:CLSK) said it is aggressively seeking new acquisition opportunities for 2021 after realizing Fiscal 2020 revenue of more than $10.0 million, the third-consecutive year of greater than 100% top-line growth. In an annual update to shareholders, the company also noted that it plans to identify partnerships and product enhancements in 2021, which it expects will expedite its growth. “Not only were we able to achieve our projected numbers (for Fiscal 2020), but the company also completed a series of strategic acquisitions that should prove to be tremendously valuable to all shareholders in the coming years,” said CleanSpark CEO Zachary Bradford in the statement. InnoCan Pharma Corporation (CSE:INNO) (OTCMKTS:INNPF) (FRA:IP4) reported it has closed a non-brokered private placement offering of 10,294,800 units of the company, at a price of $0.23 per unit, for total gross proceeds of C$2,367,804. InnoCan said it plans to use the offering proceeds for general working capital and other corporate purposes. Gevo Inc. (NASDAQ:GEVO) has had its 12-month target price increased by Noble Capital to $5.00 a share from $3.50 a share previously, with the broker maintaining an 'Outperform' rating on the stock. In a note to clients, Noble's analysts said: "We believe the high risk/high reward profile remains attractive even after the 308% stock price run since 3Q2020 results were reported. Not only is the balance sheet now debt-free, financial risk has also moderated and the prospects for 2H2021 financial closing on at least Tranche 1 (the first development phase) have improved." They added: "Additional supply commitments and hitting other milestones/catalysts would bolster the project financing prospects." American Manganese Inc. (CVE:AMY) (OTCMKTS:AMYZF) (FRA:2AM) has provided a review of 2020 company and industry highlights in lithium-ion battery recycling, manganese processing, mining exploration, and financing that have put the company in a strategic position for 2021. "2020 has been a year for the history books as we have all been faced with incredibly challenging times. I'm proud of our team and investors who have shown resilience and support as we worked to advance our technology on multiple fronts and contribute to domestic and circular supply chains," said Larry Reaugh, president and CEO of American Manganese in the statement.  "We wish everyone a prosperous New Year from all of us at American Manganese." Group Eleven Resources Corp (CVE:ZNG) (OTCMKTS:GRLVF) (FRA:3GE) reported it has closed the first tranche of a $753,000 non-brokered private placement, at an issue price of $0.065 per share, to strategic investor Michael Gentile. The company noted that the 11,584,615 shares issued will increase Gentile’s ownership interest in Group Eleven Resources to 19.9% on a partially-diluted basis. Helix BioPharma Corp. (TSX:HBP), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, announced that it has closed a private placement financing for gross proceeds of $3,000,000. The terms of the placement are for the purchase of units at $0.50 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.70 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities. ACM Alpha Consulting Management AG provided financial advisory services to Helix in connection with the private placement. Progressive Planet Solutions Inc (CVE:PLAN) said the TSX Venture Exchange has accepted for filing documentation with respect to its non-brokered private placement announced December 22, 2020, which will see the issue of 2.5 million flow-through shares at a purchase price of 10 cents each together with 1.25 million share purchase warrants with an initial exercise price of 15 cents and a one year term to expiry with four placees. Western Magnesium Corporation (CVE:WMG) (FRA:WM) (OTCMKTS:MLYF) announced that it has granted 15,650,000 incentive stock options pursuant to its Stock Option Plan for its directors, officers, advisors and consultants. The options are exercisable at a price of C$0.13 per share and 9,500,00 stock options are exercisable for a period of five years, the remaining 6,150,000 are exercisable for a period of two years. Any shares issued on the exercise of these stock options will be subject to the holding period as required by the TSX Ventures as well as any additional hold periods as required by US securities law. Ascendant Resources Inc (CVE:ASND) said the Toronto Stock Exchange reports that it has completed its review of Ascendant Resources and has determined that the company meets the exchange's requirements for continued listing.